Key result
The ajmaline challenge is discussed as a pharmacological tool to unmask electrocardiographic abnormalities diagnostic of Brugada syndrome.
Answers are grounded in this paper and cite their sources.
This editorial discusses the utility and potential pitfalls of the ajmaline challenge in diagnosing Brugada syndrome.
See doi:10.1016/S1095-668X(03)00195-7 for the article to which this editorial refers Ajmaline is a class I antiarrhythmic drug with potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation. Some years ago, thanks to the work by Miyazaki et al.,1ajmaline and other class I antiarrhythmic drugs were used to unmask the electrocardiographic abnormalities diagnostic of …
No takes yet. Share an insight, caveat, or question.
Josép Brugada (2003) conducted an editorial in Brugada syndrome. Ajmaline challenge was evaluated. The ajmaline challenge is discussed as a pharmacological tool to unmask electrocardiographic abnormalities diagnostic of Brugada syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: